D-Mannose

D-mannose is a simple sugar with a real, well-characterized biological mechanism: it binds the FimH adhesin on E. coli fimbriae and blocks the bacterium from sticking to mannose receptors on bladder epithelium, so bacteria are flushed out in urine instead of colonizing. Most uncomplicated lower UTIs are caused by uropathogenic E. coli, so the rationale is sound on paper. The question has always been whether the in-vitro story translates to fewer real-world recurrences, and the answer in 2026 looks more negative than it did three years ago.

The supportive evidence is led by Kranjcec 2014 (World Journal of Urology), an open-label three-arm randomized trial in 308 women with a recent UTI and a history of recurrence. Over 6 months of prophylaxis, 14.6% of the d-mannose 2g/day group had a recurrence versus 20.4% in the nitrofurantoin 50mg/day group and 60.8% in the untreated control. The effect size was large, the safety signal favored d-mannose, and this is the trial that everyone has been citing for a decade. Domenici 2016 in 43 women, Phé 2017 in MS patients with neurogenic bladder, and several smaller European observational studies pointed in a similar direction, and a 2020 meta-analysis by Lenger in the American Journal of Obstetrics and Gynecology pooled the available data and reported a relative risk of 0.23 versus placebo.

The 2022 Cochrane review (Cooper et al.) was the first formal pump of the brakes. It looked at 7 trials in 719 women and concluded that the evidence was of very low certainty and was insufficient to support or refute d-mannose. The reviewers flagged the open-label design of Kranjcec, the small sample sizes, the inconsistent endpoints, and the lack of double-blind placebo-controlled data in primary care populations.

The MAPLE trial answered the call. Hayward and colleagues published the result in JAMA Internal Medicine in April 2024: a double-blind, placebo-controlled randomized trial of 598 women with recurrent UTIs in 99 primary care practices in the UK, randomized to 2g d-mannose daily or matched placebo for 6 months. The primary outcome was the proportion of women contacting ambulatory care with a clinically suspected UTI. Result: 51.0% in the d-mannose group versus 55.7% in the placebo group, a difference that was not statistically significant. The authors stated explicitly that d-mannose should not be recommended for prophylaxis in this patient group. MAPLE is roughly twice the size of Kranjcec, properly blinded, conducted in the population that actually buys d-mannose, and ran on the same 2g/day protocol that the supportive trials used. The 2025 Murali Krishna meta-analysis and the 2025 Vargas meta-analysis, both of which incorporated MAPLE, found no significant benefit of d-mannose over control.

The honest read in 2026 is that the most rigorous trial of d-mannose was negative, the earlier positive trials were smaller, mostly open-label, and concentrated in single Italian or Croatian centers, and the meta-analytic signal has flipped from positive to non-significant once MAPLE is included. The mechanism is still real. The clinical benefit in the population most women use it for (recurrent uncomplicated UTI in adult primary care) has not survived a proper test. Some clinicians and patients continue to use d-mannose because the safety profile is benign, the cost is low, and the alternative for many women is long-course antibiotic prophylaxis with all of its resistance and microbiome consequences. That is a reasonable risk-adjusted choice, but it should be made with the MAPLE result in view rather than the Kranjcec result alone.

Importantly, this profile is about prevention. Acute UTI is a medical condition that needs evaluation and, in most cases, antibiotic treatment. There is no quality evidence that d-mannose treats an established symptomatic UTI, and self-treating an acute infection with d-mannose instead of seeing a clinician risks pyelonephritis, sepsis, and worse long-term urinary outcomes.